SMS Pharmaceuticals reports Q1 FY25 consolidated PAT at Rs. 16.48 Cr

SMS Pharmaceuticals has reported total income of Rs. 165.81 crores during the quarter ended June 30, 2024

Roche closes acquisition of LumiraDx’s Point of Care technology

The acquisition of LumiraDx’s Point of Care technology received all required antitrust and regulatory clearances

Concerted efforts of individual and institutions needed for organ donation and transplantation: MoS Health Anupriya Patel

Dr. Vinod Kumar Paul highlighted the huge gap between the demand for and supply of organs

HCG Manavata Cancer Centre completes world-first in robotic-assisted nipple sparing mastectomy

Supriya Lifescience names Dr. Saloni Wagh as MD

Shivani Satish Wagh takes on the role of Joint Managing Director

Aster DM Healthcare posts Q1 FY25 PAT at Rs. 74 Cr

Q1 FY25 revenues up 20% YoY to Rs. 1,002 crore

Dabur Q1 FY25 consolidated net profit up 8% at Rs 500 Cr

Q1 Consolidated operating profit Up 8.3%; revenue grows 7% to Rs 3,349 crore

DGHS conducts meeting on health promotion, healthy campus initiative and tobacco control

More emphasis should be given on investing healthcare resources towards prevention of diseases rather than only focusing on diagnostic and therapeutic options

Dr. Jitendra Singh conferred Lifetime Achievement Award

Dr. Jitendra Singh’s pioneering work on “Stress Diabetes in Kashmiri Migrants” was hailed by the World Health Organization

Bayer submits NDA to USFDA for elinzanetant for the treatment of VMS associated with menopause

The New Drug Application (NDA) includes data from the Phase III studies OASIS 1, 2 and 3 - showing elinzanetant significantly reduced the frequency and severity of moderate to severe vasomotor symptoms over 12 weeks compared to placebo